Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | SDHA | P31040 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12956120 | 1.00 | MAOA (0.47) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10197587 | 0.92 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1037132 | 0.92 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1035574 | 0.85 | MAOA (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13150711 | 0.85 | MAOA (0.52) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1033532 | 0.85 | MAOA (0.52) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1077549 | 0.83 | MAOA (0.47) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1032715 | 0.82 | MAOA (0.46) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1037657 | 0.82 | MAOA (0.47) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL1035605 | 0.81 | MAOA (0.48) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | disclosed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158827-A1 | Process for the Synthesis of Triazoles | PROKR1, SI, IL33 | MAOA 1726/4885MAOB 1344/4885PTGS1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.